America's Undersea Arsenal
Dive into a selection of defense stocks set to benefit from the $1.85 billion Virginia-class submarine program. These companies have been carefully selected by our analysts for their critical roles in building America's advanced undersea fleet.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Huntington Ingalls Industries, Inc.
HII
Current price
$265.40
Huntington Ingalls Industries is the only other U.S. shipyard capable of building nuclear-powered submarines and is a key partner with General Dynamic...
Huntington Ingalls Industries is the only other U.S. shipyard capable of building nuclear-powered submarines and is a key partner with General Dynamics in constructing the Virginia-class fleet.
Northrop Grumman Corporation
NOC
Current price
$586.23
Northrop Grumman manufactures key systems and components for submarines, including sonar systems, electronic warfare equipment, and other critical tec...
Northrop Grumman manufactures key systems and components for submarines, including sonar systems, electronic warfare equipment, and other critical technologies.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
This collection focuses on companies benefiting from confirmed government spending on naval modernization. The recent $1.85 billion contract modification creates long-term revenue visibility for defense contractors and specialized suppliers across the submarine industrial base.
What You Need to Know
These stocks represent companies throughout the submarine supply chain, from prime contractors building the vessels to specialized suppliers providing critical systems like propulsion, sonar, and combat management. They offer tactical exposure to defense sector priorities.
Why These Stocks
Each company was selected for its direct connection to the Virginia-class submarine program. This government-backed initiative provides clear, long-term revenue streams, potentially de-risking investments while supporting sustained growth across the naval defense sector.
Group Performance Snapshot
Stocks Rated Buy by Analysts
13 of 16 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 3.1% return last month.
Why You'll Want to Watch These Stocks
Guaranteed Government Spending
These companies benefit from confirmed, long-term government contracts worth billions. The Virginia-class submarine program provides revenue visibility that few other sectors can match.
National Security Priority
Naval modernization remains a top defense priority regardless of political shifts. These companies are crucial to maintaining America's undersea advantage, making them strategically important investments.
Hidden Supply Chain Gems
Beyond the big defense contractors, this collection includes specialized suppliers that fly under the radar but play critical roles in submarine construction, potentially offering overlooked growth opportunities.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beyond The App Store: Europe's New Rules
Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Frequently Asked Questions
Everything you need to know about the product and billing.